Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |
mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.02 | 0.7 |
mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.7 |
mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.7 |
mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.7 |
mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | -0.022 | 0.7 |